Active efflux of ciprofloxacin from J774 macrophages through an MRP-like transporter.
The accumulation and efflux kinetics of ciprofloxacin have been examined by using murine J774 macrophages. Accumulation (at equilibrium) was increased (three- to fourfold) (i) when cells were incubated with high extracellular drug concentrations (typically 200 mg/liter) as opposed to clinically meaningful concentrations (10 mg/liter or lower), (ii) during ATP- depletion and at acid pH, and (iii) during coincubation with probenecid, gemfibrozil and the preferential multidrug resistance-related protein (MRP) inhibitor MK571. All these conditions were also associated with a marked decrease in ciprofloxacin efflux (half-lives increased from <2 min in controls to up to 10 min). Monensin (a proton ionophore), verapamil, and the preferential P-glycoprotein (P-gp) inhibitor GF120918 had no or only minimal effect, while cyclosporin A, which is not specific for P-gp but also acts on MRP, had an intermediate effect. Short-term uptake studies showed that the influence of the modulators on the apparent drug influx was almost immediate (delay of < or =1 min). Cells made resistant to probenecid and showing a marked overexpression of MRP1 (by Western blot analysis and confocal microscopy) accumulated ciprofloxacin to almost the same extent as did control cells, but efflux was inhibited less by probenecid, gemfibrozil, and MK571. We conclude that ciprofloxacin is subject to constitutive efflux in J774 macrophages through the activity of an MRP-related transporter which is probably distinct from MRP1. We also suggest that the cellular accumulation of ciprofloxacin in wild-type cells is constitutively impaired at therapeutically meaningful concentrations.
Michot
Jean-Michel
JM
Unité de Pharmacologie Cellulaire et Moléculaire, Université Catholique de Louvain, UCL 7370, Ave. E. Mounier 73, B-1200 Brussels, Belgium.
Van Bambeke
Françoise
F
Mingeot-Leclercq
Marie-Paule
MP
Tulkens
Paul M
PM
D000255:Adenosine Triphosphate / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000378:metabolism*; D017963:Azithromycin / Q000494:pharmacology; D015153:Blotting, Western; D002352:Carrier Proteins / Q000378:metabolism; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002939:Ciprofloxacin / Q000378:metabolism*; D004247:DNA / Q000096:biosynthesis / Q000235:genetics; D004351:Drug Resistance; D018432:Drug Resistance, Multiple / Q000235:genetics*; D005978:Glutathione / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007476:Ionophores / Q000494:pharmacology; D008264:Macrophages / Q000378:metabolism*; D018613:Microscopy, Confocal; D008858:Microscopy, Phase-Contrast; D008985:Monensin / Q000494:pharmacology; D011339:Probenecid / Q000494:pharmacology; D011522:Protons; D012076:Renal Agents / Q000494:pharmacology; D013438:Sulfhydryl Compounds / Q000378:metabolism
D000890:Anti-Infective Agents; D002352:Carrier Proteins; D007476:Ionophores; D011522:Protons; D012076:Renal Agents; D013438:Sulfhydryl Compounds; D002939:Ciprofloxacin; D017963:Azithromycin; D000255:Adenosine Triphosphate; D004247:DNA; D008985:Monensin; D005978:Glutathione; D011339:Probenecid